Catalysts / VNDA
Upcoming FDA decisions and readouts we track for Vanda Pharmaceuticals, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Vanda Pharmaceuticals (VNDA, listed on Nasdaq). It concerns Quimilza (imsidolimab) (Generalised pustular psoriasis).
First on the list: the PDUFA date for Quimilza (imsidolimab) (Generalised pustular psoriasis), dated 12 Dec 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals VNDA · Nasdaq | Quimilza (imsidolimab) | Generalised pustular psoriasis | 12 Dec 2026 in 66d |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList